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Summary: Monoclonal antibodies against human thyroglobulin were produced by the hybridoma technique.
Using three non-crossreactive monoclonal antibodies, an IRMA system was developed, with a polyclonal
rabbit antibody fixed on microtiter plates as first extracting antibody. The monoclonal antibodies were used
as second antibody, while anti-mouse IgG-biotin from goat and [I25l]streptavidin served as the indicator
system. The source of the monoclonal antibodies was diluted culture medium without purification. Sensitivities
of 3—4 g/l were obtained with all 3 monoclonal antibodies; interassay variation was about 5%. This test
system will be used for further immunological characterization of circulating thyroglobulin in different thyroid
diseases.
Introduction dence that tumour thyroglobulin is different from
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 v , this is of diagnostic importance,the blood stream is still unclear. Thyroglobulin has a
molecular weight of about 660 000 and is composed We have developed an immunoradiometric system for
of two polypeptide chains and a carbohydrate moiety the measurement of serum thyroglobulin which can
of about 10% of the molecular weight (1). Micro- use different non-crossreactive monoclonal antibodies
heterogeneity of thyroglobulin is a well-known phe- against thyroglobulin.
nomenon; it might be partly due to different extents
of iodination of the subunits and variations of the ^. . . . ,
 A. .. ,
t f , . Materials and Methodscarbohydrate moiety.
Materials
For the clinician, thyroglobulin is a very important _ . , . . . „4 4 . __ ,«OACX ^, T u
" , ' . / ' Jr«
 r . - Titertek microtitre plates (Titertek 77-17305) from Flow Lab.;
tumour marker m the follow-up of patients treated
 rabbit anti-human thyroglobulin immunoglobulins from Dako-
for differentiated thyroid cancer. There is some evi- patts; thyroglobulin standard and [I25l]labeled thyroglobulin
from Henning Berlin GmbH; goat anti-mouse immunoglobulin-
biotin and [nsl]streptavidin from Amersham; gelatin from
') This work was supported by a grant of the Tumorzentrum Serva, Heidelberg. All other reagents were of the usual analyt-
Heidelberg/Mannheim. ical grade.
J. Clin. Chem. Clin. Bioehem. / Vol. 26,1988 / No. 7
436 Pfahl et al.: Immunoradiometric assays for human thyroglobulin
Product ion of monoclonal antibodies
Monoclonal antibodies were produced by the hybridoma tech-
nique as described previously (7). In short: Balb/C mice were
injected several times with 0.5-1.0 mg human thyroglobulin
which had been extracted from euthyroid goiters by ammonium
sulphate precipitation. Spleen cells were fused with X 63 Ag
8.653 myeloma cells 3 days after the last booster injection.
Supernatants of growing clones were screened for thyroglobulin
antibody by RIA (50 μΐ supernatant, 50 μΐ [125Ι]thyroglobulin
(Henning/Berlin), 400 μΐ tris HC1 pH 7.4 + 10 g/1 bovine serum
albumin).
Ant ibody purification
Monoclonal antibodies were purified from supernatants of iso-
lated clones (50-100 ml) by Affi-Gel Protein A MAPS, Bio-
Rad.
Purified antibody was iodinated with 125I by the chloramine Τ
method as described previously (7). The iodinated monoclonals
were used in cross inhibition experiments.
General design of the immunoradiometric assay
Microtitre plates were coated with 50 μΐ rabbit anti-human
thyroglobulin IgG in carbonate buffer, pH 10.6, 0.2 mol/1 for
20 h at 4 °C. This was followed by a blocking step to absorb
unoccupied binding sites (10 g/1 gelatin for 1 h). After washing
3 times with phosphate buffered saline, thyroglobulin standards
or unknown samples (50 μΐ) were incubated for 2 h at room
temperature. After another washing step (3 times phosphate
buffered saline) monoclonal antibody was incubated for 1 h.
This was followed by a further wash (3 times phosphate buff-
ered saline) and incubation with goat anti-mouse IgG-biotin.
There was no crossreaction of the anti-mouse IgG-biotin with
the coated rabbit IgG. Finally, after intensive washing (4 times
phosphate buffered saline), [125I]labeled streptavidin was applied
for 1 h. After a final washing step (3 times phosphate buffered
saline), the wells were counted in a gamma counter. All phos-
phate buffered saline solutions for washing contained 5 ml/1
Tween 20.
Results
Using cross blocking experiments, we selected 3
monoclonal antibodies, specific for 3 different anti-
genie epitopes. An example of such experiments is
shown in figure 1 for labeled antibodies Tg 11 and
Tg 13. Both antibodies were purified by protein A
sepharose and labeled by the chloramine T method.
As demonstrated, binding of labeled Tg 11 was inhib-
ited by antibodies 48, 46, 62, 67, whereas antibody
13 showed no crossreaction with these antibodies. For
further studies the non-crossreacting antibodies Tg
11, Tg 13 and Tg 40 were chosen; the affinity constants
of the three antibodies, calculated by the method of
Mw/fer(8),werel.02 χ ΙΟ101/mol (Tg 11), 3.2 χ ΙΟ10
1/mol (Tg 13) and 1.15 χ ΙΟ9 1/mol (Tg 40); all anti-
bodies were of the IgG2 class.
Figure 2 shows the results obtained by varying the
coating (first) antibody. Three thyroglobulin concen-
trations in buffer were used and the procedure was
performed as described in the section on materials
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Unlabelled monoclonal antibody
Cross-blocking experiments with the [125I]labeled mono-
clonal antibodies Tg 1 1 and Tg 13. The abscissa indicates
the respective unlabeled monoclonal antibody which
was preincubated. Microtitre plates were coated with
human thyroglobulin (10 mg/1). Binding of labeled Tg
11 and Tg 13 without preincubation with cold antibody
was set at 1.00.
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Fig. 2. Different concentrations of rabbit anti-human thyro-
globulin IgG were coated (a- 1:1000; o— 1:2000;
x- 1:4000; Δ - 1:8000) followed by incubation with
3 concentrations of human thyroglobulin (10,100,1000
μg/l); second antibody: Tg 13 (1:10); finally, goat anti-
mouse IgG-biotin as described under "Methods".
and methods. The second antibody in this case was
Tg 13, and after incubation with anti-mouse IgG-
biotin, radioactive streptavidin was counted. The op-
timal titre of the coating antibody was about 1:2000;
this titre was used in further experiments.
Figure 3 shows the test results obtained with varia-
tions of the monoclonal antibody, in this case Tg 13.
It is obvious that the supernatant of the clone Tg 13
contains antibody in excess, and we decided to use a
1:10 dilution of this particular supernatant. It seems
important to determine the optimal concentrations
for each monoclonal antibody, ΐρ* avoid results that
contain unnecessarily high levels of unspecific bind-
ing.
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Fig. 3. Coating with rabbit anti-human thyroglobuiin IgG
1:2000. Different titres of the second antibody (Tg 13).
o- 1:2; x- 1:20; o- 1:100. Other conditions as in
figure 2.
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Fig. 4. Different titres of goat anti-mouse IgG-biotin; further
conditions as in figure 2.
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Fig. 5. Dependence of unspecific binding on variations of goat
anti-mouse IgG-biotin; conditions as in figure 2.
Finally we investigated the effect of different amounts
of biotin-labeled anti-mouse IgG in this system. Fig-
ure 4 demonstrates that increasing amounts of anti-
mouse IgG-biotin led to increased binding of
[125I]avidin. However, as shown in figure 5, increasing
the titre from 1:1000 to 1:500 results in an dispro-
portionate increase of nonspecific binding. This means
that most of the increasing counts observed with high
concentrations of anti-mouse IgG-biotin are due to
nonspecific binding. Most of this nonspecific binding
seems to be due to some residual cross-reactivity of
the anti-mouse IgG with the coated rabbit anti human
thyroglobulin IgG. The optimal concentration of anti-
mouse IgG-biotin is in the titre range of 1:1000 to
1:2000. Figure 4 and 5 demonstrate that a compro-
mise has to be accepted between optimal specific
binding and minimal nonspecific binding. We chose
a titre of 1:1000 because the nonspecific binding of
2000 counts/min seemed reasonable in comparison to
the steepness of the curve. However, it might turn out
that conditions with lower nonspecific binding might
be preferential, especially in the lower thyroglobulin
concentration range. It becomes evident from this
experiment that anti-mouse IgG-biotin is one of the
limiting factors in this system, and that it is impossible
to use this reagent in excess.
Table 1 summarized the exact conditions of the IRMA
worked out by the demonstrated experiments, and
figure 6 shows standard curves of 3 different assays
with 3 different monoclonal antibodies in serum
standards. The levelling off in the high concentration
range, which is usually not seen in conventional
IRMA systems, is due to the above-mentioned limi-
tation on the amount of anti-mouse IgG-biotin which
Tab. 1. Flow diagram for a human thyroglobulin IRMA with
monoclonal antibodies using the biotin-avidin system
1. Coat Titertek microtitre plates with rabbit anti-human
thyroglobulin (pH 10.6, 50 μΐ; 1:2000, from Dakopatts)
2. Block with 10 g/1 gelatin, l h
3. Wash 3x with phosphate buffered saline
4. Incubate 50 μΐ standard or sample diluted 1:2 with phos-
phate buffered saline, 2 h
5. Wash 3 χ with phosphate buffered saline
6. Add monoclonal antibody, 50 μΐ, in appropriate dilution,
l h
7. Wash 3 x with phosphate buffered saline
8. Add goat anti-mouse IgG-biotin (Amersham), 1:1000—
1:2000 in phosphate buffered saline, 50 μΐ, l h
9. Wash 4 χ with phosphate buffered saline
10. Add streptavidin 125I (100000 counts/min) 50 μΐ, l h
11. Wash 3 χ with phosphate buffered saline, count.
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Fig. 6. Standard curves of 3 different non-cross-reacting mouse
monoclonal antibodies; o— Tg 13; x— Tg 40; A — Tg
11 (II. antibody). I. antibody: rabbit polyclonal anti-
human thyroglobulin IgG. For exact conditions see
table 1.
can be used in this system. In table 2 some statistical
data of these three assay systems are summarized.
The sensitivity (three standard deviations at zero
point) and the intra- and inter-assay variations (at 50
μ§/1) are similar in all 3 systems and seem comparable
with those of most polyclonal assays.
Tab. 2. Analytical performance of the assays
Sensitivity ^g/l)
Intra-assay variation
(20 μδ(1) η = 10
IRMA
Tg 13
4.0
1.1%
IRMA
Tg 11
3.0
2.6%
IRMA
Tg 40
3.0
1.8%
Inter-assay variation
(20 μβ/1) η = 8
Recovery (50 μg/Γ)
n = 8; χ ± SD
5.4% 1.5% 4.8%
52.8 ± 2.8 49.7 ± 0.76 55.2 ± 4.0
Henning standard
Using this system in 12 normal individuals plasma
thyroglobulin concentrations were measured simul-
taneously. The mean value obtained was 17.2 μg/l for
Tg 11, 20.3 μg/l for Tg 13 and 20.6 μ^ for Tg 40.
The difference was statistically n f significant.
Discussion
Monoclonal antibodies are widely used today in di-
agnostic tests for different hormones and various
drugs. Several tests, for instance the thyrotropin assay,
have been considerably improved, especially by use
of the IRMA technique.
Thyroglobulin is a very complex macroinolecule and
it is still unproven whether the use of monoclonal
antibodies will be of advantage in the radioimmuno-
logical determination of serum thyroglobulin. In par-
ticular, the possibility of tumour-specific variants of
antigenic epitopes of thyroglobulin might be a prob-
lem (3, 4, 6, 8). On the other hand, it might be possible
to develop a thyroglobulin test system which is not
influenced by autoantibodies, because the epitope
specificity of autoantibodies seems to be very limited
(9).
We describe an IRMA system for thyroglobulin meas^·
urement in serum which uses a polyclonal rabbit an-
tibody as first extracting antibody and mouse mono-
clonal antibody as second. The second antibody con-
sists of diluted culture medium of specific unlabelled
clones. A biotin-labeled anti-mouse IgG (goat) and
[125I]labeled avidin serve as indicators. Thus the mon-
oclonal antibodies can easily be exchanged for differ-
ent epitope specificity. By the systematic use of dif-
ferent non cross-reacting monoclonal antibodies we
are now able to investigate the preservation or dele-
tion of various antigenic epitopes of serum thyro-
globulin in thyroid cancer patients. By this sensitive
device we will be able to clarify whether the postulated
increased immunological heterogeneity of tumour
thyroglobulin really exists and, if so, whether it is of
diagnostic significance. In general, it will be possible
to investigate whether thyroglobulin species specific
for thyroid disease can be found in the circulation.
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